Variation in dermcidin expression in human tumors
Author Information
Author(s): Stewart G D, Skipworth R J E, Pennington C J, Lowrie A G, Deans D A C, Edwards D R, Habib F K, Riddick A C P, Fearon K C H, Ross J A
Primary Institution: University of Edinburgh
Hypothesis
The study aimed to evaluate dermcidin expression in cell lines following simulation of tumor microenvironmental conditions and in a range of primary tumors.
Conclusion
Dermcidin expression varies significantly between different cancer types, with prostate cancer showing no expression and pancreatic cancer showing moderate to high levels.
Supporting Evidence
- None of the primary prostate tissue samples expressed dermcidin mRNA.
- 60% of pancreatic cancer samples showed moderate to high levels of dermcidin expression.
- Only 4% of gastro-oesophageal cancer samples expressed moderate quantities of dermcidin mRNA.
Takeaway
This study looked at how a protein called dermcidin behaves in different types of cancer, finding that it is not present in prostate cancer but is found in some pancreatic cancers.
Methodology
The study used real-time PCR to assess dermcidin mRNA levels in various cancer cell lines and primary tumor samples.
Limitations
The study did not include samples from distant metastatic deposits, which may express high levels of dermcidin.
Participant Demographics
Patients with oesophageal, gastric, pancreatic, bile duct, and prostate cancers, as well as benign tissue samples.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website